Advertisement
Advertisement
MGX
Metagenomi Therapeutics, Inc. Common Stock
1.20
USDSponsored
-0.04
-3.23%
Jun 24, 14:43 UTC -4
Closed
After-Market
1.21
+0.01
+0.42%
MGX Earnings Reports
Positive Surprise Ratio
MGX beat 7 of 10 last estimates.
70%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$3.87M
/-$0.56
Implied change from Q1 26 (Revenue/ EPS)
+210.23%
/-8.20%
Implied change from Q2 25 (Revenue/ EPS)
-54.52%
/+3.70%
Metagenomi Therapeutics, Inc. Common Stock earnings per share and revenue
On May 11, 2026, MGX reported earnings of -0.61 USD per share (EPS) for Q1 26, missing the estimate of -0.53 USD, resulting in a -14.68% surprise. Revenue reached 1.25 million, compared to an expected 5.98 million, with a -79.15% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.56 USD, with revenue projected to reach 3.87 million USD, implying an decrease of -8.20% EPS, and increase of 210.23% in Revenue from the last quarter.
FAQ
What were Metagenomi Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Metagenomi Therapeutics, Inc. Common Stock reported EPS of -$0.61, missing estimates by -14.68%, and revenue of $1.25M, -79.15% below expectations.
How did the market react to Metagenomi Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved -- 0%, changed from $1.35 before the earnings release to $1.35 the day after.
When is Metagenomi Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Metagenomi Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Metagenomi Therapeutics, Inc. Common Stock is expected to report EPS of -$0.56 and revenue of $3.87M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement